These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 11111207)

  • 1. Treatment satisfaction of patients with lower urinary tract symptoms: randomised controlled trials vs. real life practice.
    Michel MC; Goepel M
    Eur Urol; 2000; 38 Suppl 1():40-7. PubMed ID: 11111207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical treatment modalities for lower urinary tract symptoms: what are the relevant differences in randomised controlled trials?
    Zimmern P
    Eur Urol; 2000; 38 Suppl 1():18-24. PubMed ID: 11111205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Invasive and minimally invasive treatment modalities for lower urinary tract symptoms: what are the relevant differences in randomised controlled trials?
    Tubaro A; Vicentini C; Renzetti R; Miano L
    Eur Urol; 2000; 38 Suppl 1():7-17. PubMed ID: 11111204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha1-blocker therapy for lower urinary tract symptoms suggestive of benign prostatic obstruction: what are the relevant differences in randomised controlled trials?
    De Mey C
    Eur Urol; 2000; 38 Suppl 1():25-39. PubMed ID: 11111206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How are lower urinary tract symptoms managed in real life practice? The French experience.
    Vallancien G
    Eur Urol; 2000; 38 Suppl 1():54-9. PubMed ID: 11111209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimally invasive therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    Elhilali MM
    J Urol; 2007 Mar; 177(3):820-1. PubMed ID: 17296350
    [No Abstract]   [Full Text] [Related]  

  • 7. To what extent do real life practice studies differ from randomized controlled trials in lower urinary tract symptoms/benign prostatic hyperplasia?
    Mishra V; Emberton M
    Curr Opin Urol; 2006 Jan; 16(1):1-4. PubMed ID: 16385193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
    Djavan B; Marberger M
    Eur Urol; 1999; 36(1):1-13. PubMed ID: 10364649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Gallegos PJ; Frazee LA
    Pharmacotherapy; 2008 Mar; 28(3):356-65. PubMed ID: 18294115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of lower urinary tract symptoms suggestive of benign prostatic obstruction in real life practice in France.
    Vallancien G; Pariente P
    Prostate Cancer Prostatic Dis; 2001; 4(2):124-131. PubMed ID: 12497050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Scoring the short form ICSmaleSF questionnaire. International Continence Society.
    Donovan JL; Peters TJ; Abrams P; Brookes ST; de aa Rosette JJ; Schäfer W
    J Urol; 2000 Dec; 164(6):1948-55. PubMed ID: 11061889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benign prostatic hyperplasia and lower urinary tract symptoms: evidence and approaches for best case management.
    Barkin J
    Can J Urol; 2011 Apr; 18 Suppl():14-9. PubMed ID: 21501546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FAQs: lower urinary tract symptoms in men.
    Belal M; Abrams P
    Practitioner; 2004 Sep; 248(1662):652, 654, 656 passim. PubMed ID: 15376550
    [No Abstract]   [Full Text] [Related]  

  • 14. Guideline for the primary care management of male lower urinary tract symptoms.
    Speakman MJ; Kirby RS; Joyce A; Abrams P; Pocock R;
    BJU Int; 2004 May; 93(7):985-90. PubMed ID: 15142148
    [No Abstract]   [Full Text] [Related]  

  • 15. A pooled analysis of individual patient data from registrational trials of silodosin in the treatment of non-neurogenic male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH).
    Novara G; Chapple CR; Montorsi F
    BJU Int; 2014 Sep; 114(3):427-33. PubMed ID: 24571313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lower urinary tract symptoms smorgasbord: international fare.
    Barry MJ
    J Urol; 1997 Mar; 157(3):900-1. PubMed ID: 9072595
    [No Abstract]   [Full Text] [Related]  

  • 17. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe.
    Chapple CR; Montorsi F; Tammela TL; Wirth M; Koldewijn E; Fernández Fernández E;
    Eur Urol; 2011 Mar; 59(3):342-52. PubMed ID: 21109344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
    Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
    BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment satisfaction with tadalafil or tamsulosin vs placebo in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH): results from a randomised, placebo-controlled study.
    Oelke M; Giuliano F; Baygani SK; Melby T; Sontag A
    BJU Int; 2014 Oct; 114(4):568-75. PubMed ID: 24612148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New clinical evidence of silodosin, an α(1A) selective adrenoceptor antagonist, in the treatment for lower urinary tract symptoms.
    Yoshida M; Kudoh J; Homma Y; Kawabe K
    Int J Urol; 2012 Apr; 19(4):306-16. PubMed ID: 22251148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.